Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG Fresenius for prevention of chronic graft-versus-host disease after sibling allogeneic peripheral blood stem cell transplantation
2005-005719-83Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Aug 2006
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Cumulative incidence of chronic graft-versus-host disease. Started Aug 2006; status: completed.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2005-005719-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005719-83.